NewAmsterdam Pharma and Menarini Group Achieve Key Milestone with Positive CHMP Opinion on Ubeslo® and Evlarco®

NewAmsterdam Pharma and Menarini's Recent CHMP Milestone

On July 25, 2026, NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical firm, in collaboration with the Menarini Group, announced a significant development in the realm of cardiovascular health: the Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two key products, Ubeslo® and Evlarco®. This favorable opinion marks a crucial step toward making innovative treatments for high cholesterol and cardiovascular risk more accessible in Europe.

The Significance of CHMP’s Favorable Opinion

The CHMP's recommendation is not only significant for NewAmsterdam but also promises to fill a crucial gap for patients with primary hypercholesterolemia. Ubeslo® is a monotherapy based on obicetrapib, while Evlarco® combines obicetrapib with ezetimibe. Both medications aim to effectively reduce low-density lipoprotein cholesterol (LDL-C), which remains a major cardiovascular risk factor. The European Medicines Agency (EMA) now takes this opinion into account as it prepares for a final decision expected in the second half of 2026.

Dr. Michael Davidson, CEO of NewAmsterdam Pharma, expressed his enthusiasm regarding this progress. He emphasized that these products could address significant unmet needs among patients who struggle to reach LDL-C targets with existing therapies.

Clinical Trial Successes

The positive recommendation was grounded on the results of various Phase III clinical trials, including particularly successful studies like BROADWAY, BROOKLYN, and TANDEM. These trials reported statistically significant reductions in LDL-C, with Ubeslo® proving to lower it by up to 40% compared to placebo, while Evlarco® achieved reductions of around 50%. Moreover, both treatments exhibited a tolerance profile similar to that of placebo, which is vital for patient compliance and safety.

The ongoing Phase III trials under NewAmsterdam and Menarini's stewardship further bolster the confidence surrounding obicetrapib. Trials such as PREVAIL, focusing on cardiovascular outcomes, are aimed at determining the broader impact of obicetrapib on major adverse cardiovascular events.

Anticipated Developments

NewAmsterdam and Menarini are currently focused on the European Commission's final decision. Elcin Barker Ergun, CEO of Menarini, noted the excitement surrounding this regulatory milestone and the possibility of making obicetrapib available to those who have yet to achieve their LDL-C targets despite using standard treatments. Notably, Menarini is responsible for the commercialization of obicetrapib across Europe, thanks to their exclusive licensing agreement.

The partnership is set to yield tiered royalties ranging up to 25% for NewAmsterdam based on net revenue generated from this new treatment, alongside the potential to earn up to 833 million euros tied to meeting clinical and regulatory milestones.

The Importance of Addressing Cardiovascular Diseases

Cardiovascular diseases (CVDs) remain the leading cause of death globally. Despite the availability of various lipid-lowering therapies, the effectiveness of existing treatments has not sufficiently addressed LDL-C targets. With the looming projection that over 184 million adults in the U.S. will be affected by CVDs by 2050, the necessity for effective treatments like obicetrapib cannot be understated. The data paint a concerning picture, where many patients remain undertreated despite the issuance of approximately 269 million lipid-lowering prescriptions over a single year.

As studies indicate that significant portions of patients with atherosclerotic cardiovascular disease (ASCVD) fail to meet LDL-C objectives, the urgency for innovative solutions underscores the potential impact of obicetrapib in clinical practice. This resource could not only improve individual patient outcomes but also contribute to overall public health goals in managing cardiovascular risks effectively.

Conclusion

In summary, NewAmsterdam and Menarini’s progress with Ubeslo® and Evlarco® signifies a meaningful step forward in the realm of cardiovascular disease management. As they await the European Commission's decision, the potential for these groundbreaking therapies to meet the needs of patients remains a beacon of hope for those affected by high LDL-C levels and related cardiovascular risks. As the biopharmaceutical landscape continues to evolve, the collaboration between NewAmsterdam and Menarini may usher in a new era of treatment options for patients in Europe and beyond.